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CYCLOOXYGENASE-2 EXPRESSION IN POST-MASTECTOMY CHEST WALL RELAPSE.  
Janet H. Kim1, Veerle Bossuyt2, Teresa Ponn3, Donald Lannin3, Bruce G. Haffty4.  Departments of 
Therapeutic Radiology1, Pathology2, and Surgery3, Yale University School of Medicine, New 
Haven, Connecticut and Department of Radiation Oncology4, Robert Wood Johnson Medical 
School, New Brunswick, New Jersey. 
 
The purpose of this study was to assess the prognostic significance and clinical correlations of 
cyclooxgenase-2 expression (COX) in a cohort of patients treated with radiation (RT) for post-
mastectomy chest wall relapse (PMCWR).  Between 1975 and 1999, 113 patients were treated for 
isolated PMCWR.  All patients were treated with biopsy and/or excision of the CWR followed by 
RT. Median follow-up was 10 years. All clinical data including demographics, pathology, staging, 
receptor status, HER-2/neu status, and adjuvant therapy were entered into a computerized 
database.  Paraffin-embedded CWR specimens were retrieved from 42 patients, of which 38 were 
evaluated, created into a tissue microarray, stained by immunohistochemical methods for COX, 
and graded 0-3+.  A score of 2-3+ was considered positive.  Overall survival from original 
diagnosis for the entire cohort was 44% at 10 years.  Survival rate after chest wall recurrence was 
28% at 10 years.  The distant metastasis-free survival rate after CWR was 40% at 10 years.  Local-
regional control of disease was achieved in 79% at 10 years after CWR. COX was considered 
positive in 13 of 38 cases.  COX was inversely correlated with ER (p= .045) and PR (p = .028), 
and positively correlated with HER-2/neu (p =.003). COX was also associated with a shorter time 
to PMCWR. The distant metastasis-free rate for COX negative patients was 70% at 10 years, 
compared with 31% at 10 years for COX-2 positive patients (p = 0.029).   COX positive had a 
poorer local-regional progression-free rate of 19% at 10 years, compared with 81% at 10 years for 
COX negative (p = 0.003).  Outcome following RT for PMCWR is relatively poor. Positive COX 
correlated with other markers of poor outcome including a shorter time to local relapse, negative 
ER/PR and positive Her-2/neu status. Positive COX correlated with higher distant metastasis and 
lower local-regional control of disease. If confirmed with larger studies, these data have 
implications with respect to the concurrent use of COX-2 inhibitors and radiation for PMCWR.   
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 Breast cancer is the leading cancer among women and the second most 
common cause of cancer death in women after lung cancer.  It is the main cause of 
death in women ages 45 to 55. (1)  Breast cancer rates have increased by 1.2 % per year 
from 1940 to 1980.  Each year, approximately 180,000 American women are 
diagnosed with breast cancer and 40,000 die from the disease. (1)  Although the most 
important risk factor for the development of breast cancer is age, risk may be affected 
by age at menarche, first pregnancy, age at menopause, use of exogenous estrogens, 
and family history.  A variety of pathologic findings may be discovered at the time of 
diagnosis, but the most important distinction from the standpoint of treatment has been 
between invasive and non-invasive (in situ) cancer.  Invasive (infiltrating) ductal 
carcinoma is the most common type of breast cancer, while ductal carcinoma in situ 
(DCIS) comprises approximately 15-20% of all breast cancer.  Although early 
detection and improved treatment modalities over the years have increased survival 
rates, extensive efforts have been directed at improving outcomes with more targeted 
therapies.  Various factors may affect the treatment of localized breast cancer.  These 
include the size and extent of the tumor, spread of cancer to lymph nodes, tumor 
markers, and hormone receptors.  Current treatment options for breast cancer are often 
integrated into a multi-modality approach by including various combinations of 
surgery, chemotherapy, hormone therapy, and radiation therapy.  Regarding 
chemotherapy, anthracycline-based regimens are often chosen due to their significant 
benefit compared to nonanthracycline-containing adjuvant chemotherapy such as 
cyclophosphamide, methotrexate, plus fluorouracil, or CMF.(1)  Surgery may involve 
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mastectomy or lumpectomy (breast-conserving surgery) with or without lymph node 
dissection.  Lumpectomy is usually accompanied by radiation therapy to the entire 
breast.  Despite the increasing use of breast conserving surgeries for breast cancer, 
mastectomy still plays a large role in primary and salvage treatment.   
Unfortunately, despite the attempted removal of all breast tissue during a 
mastectomy, local-regional recurrences (LRR) still occur.  About 10-20% of all 
patients develop a local recurrence, mostly within the boundaries of the chest wall, 
within a 10 year period despite achieving negative surgical margins. (2-9)   Boundaries 
of the chest wall extend from the supraclavicular line to the diaphragm, and from the 
sternum to the mid-axillary line.  Local-regional recurrence may occur in the skin, 
subcutaneous tissue, muscle, or bone of chest wall. The three most common sites of 
local-regional recurrence in decreasing order are the chest wall, supraclavicular 
region, and axilla.  The most frequent site for recurrence in the chest wall is in the scar 
or grafted area from previous mastectomy.  Most local recurrences occur within a 3 
year period after mastectomy. (10) 
Local-regional recurrences are significant because they often cause 
considerable morbidity and distress to patients.  A recurrence may present as a rash-
like lesion, induration, nodule or ulcer.  Poor circulation and relatively rapid tumor 
growth may prolong healing time for lesions such as ulcers.  In one study by 
Bedwinek et al, 62% of patients with uncontrolled LRR experienced one or more of 
the following problems: bleeding and/or ulceration, pain, arm edema, and brachial 
plexus paralysis.(11) 
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Another study by Bedwinek et al attempted to identify the natural history after 
LRR and to identify clinical factors that would predict which subsets of patients would 
have a good prognosis.(12)  A retrospective study was performed of 129 patients with 
chest wall relapse after mastectomy who then received radiation only, excision only, 
or both.  Factors that determined good prognosis were single recurrence, size of largest 
recurrence less than 1 cm, and a disease-free interval of greater than 2 years.  All of 
these factors had a significant effect on disease-free survival and overall survival.  
Overall survival and disease-free survival at 5 years from primary diagnosis were 
found to be 36% and 13% respectively, while 81% of patients eventually developed 
distant metastases.  The time to develop distant metastases was longer for patients 
with good prognostic factors.  
A large study performed by Recht et al in 1999 demonstrated the correlation 
between the number of positive nodes and tumor size at the time of primary diagnosis 
to incidence of local-regional failure. (13)  Among patients with 1-3 positive lymph 
nodes at  primary diagnosis, the 10-year cumulative incidence of isolated local-
regional failure increased with increasing tumor size.  Among patients with T2 stage, 
the 10-year cumulative incidence of local-regional failure more than doubled between 
those who had 1 to 3 positive lymph nodes compared to those who had 4 to 7 positive 
lymph nodes.  These results show that the incidence of local-regional failure was 
positively correlated with number of positive lymph nodes and tumor size. 
Treatment for chest wall relapses often consists of surgical excision when 
feasible followed by radiation therapy to the area of recurrence.  Patients are treated up 
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to 50 Gy for completely excised recurrent tumors.  For unresected lesions, 60-65 Gy is 
given for lesions less than 3 cm while 65-75 Gy is given for lesions greater than 3 cm.   
Prognosis is poor for patients who develop a chest wall relapse.  Five-year 
postrecurrence survival rates range from 36% to 53% (4, 5, 9, 12, 14-19)  while disease-free 
survival rates range from 13% to 44%.(4, 12, 16, 18, 19)  Thus, these women represent a 
high-risk subgroup with respect to systemic recurrence and mortality.  In addition to 
this, these patients also face significant morbidity as stated before due to the 
aggressive nature of their tumors.  Although various clinical and pathological 
parameters have been indicated as prognostic factors for disease-free and overall 
survival after local-regional recurrence, there is a need to examine molecular markers 
as prognostic tools to aid clinical management.   
One molecular marker that has been the subject of active research is 
cyclooxygenase-2 (COX-2).  COX-2 has been identified as a tumor marker associated 
with poor prognosis in various cancers based on epidemiological, preclinical and 
translational studies. Cyclooxygenase is a well-known enzyme in the inflammatory 
pathway that catalyzes the conversion of arachidonic acid to prostaglandin H2, the 
rate-limiting step in the formation of prostaglandins from membrane phospholipids.  
There are two forms of cyclooxygenase: COX-1 and COX-2.  COX-1 is known to be 
constituitively expressed in a variety of mammalian cells.  Its role has been linked to 
physiological functions such as the cytoprotection of the stomach and control of 
platelet aggregation.(20) In contrast, COX-2 is thought to be upregulated in response to 
growth factors, tumor promoters, cytokines, and several oncogenes.(21-23)  
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Active research has been directed at exploring the association between COX-2 
and carcinoma.  As a result, COX-2 has been found to be overexpressed in various 
cancers such as lung, cervical, head and neck, colon, and pancreas. (24-29)  One study 
evaluated the prognostic significance of elevated COX-2 expression in a cohort of 
primary resected lung adenocarcinomas.(24)  A significant relationship was established 
between increased COX-2 expression and shortened patient survival only in a cohort 
of patients with stage I disease (p = 0.034). In one study by Gaffney et al, increased 
expression of COX-2 was found to be associated with poorer overall and disease-free 
survival in a cohort of cervical carcinoma patients treated with definitive radiation 
therapy.(28)  Another study evaluating squamous cell carcinoma of head and neck 
cancers (HNSCC) demonstrated that mean levels of COX-2 mRNA were increased by 
nearly 150-fold in HNSCC compared with normal oral mucosa from healthy 
volunteers.(30)  A study evaluating pancreatic cancers demonstrated increased 
expression of COX-2 protein in pancreatic carcinomas compared to benign tumors. (29)  
Knocking out the COX-2 gene in murine models of familial adenomatous polyposis 
was shown in a study by Oshima et al to decrease the number and size of intestinal 
polyps.(31)  Expression of COX-2 has also been studied in human transitional cell 
carcinoma of the urinary bladder.(32)  COX-2 immunoreactivity was detected in 66% of 
the carcinomas, whereas only 25% of the non-neoplastic samples were positive (p < 
0.005). 
 Furthermore, there has been increasing evidence of the role of COX-2 in 
breast cancer.  COX-2 is expressed in about 40% of human breast cancers, and is 
associated with poor prognosis.(33)   The possible role of COX-2 in breast cancer was 
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first noted when elevated levels of prostaglandins were found in breast tumor cells.(34-
36) A study in rat models subsequently demonstrated that forced overexpression of 
COX-2 induced breast cancer.(37) Translational studies have also confirmed the 
positive correlation between these two parameters. Ristimaki et al found that 37.4% of 
invasive cancers analyzed by immunohistochemistry were found to have positive 
COX-2 expression.  In another study, 43% of invasive cancers and 63% of ductal 
carcinomas in situ (DCIS) were found to stain positively for COX-2 by 
immunohistochemical methods.(38)  Positive COX-2 expression has also been 
correlated with decreased distant disease-free survival, large tumor size, high 
proliferation rate, and human epidermal growth factor receptor 2 (HER-2) gene 
amplification.(20) These studies suggest that COX-2 inhibition may play a potential 













STATEMENT OF PURPOSE 
The main objective of this analysis was to retrospectively determine whether a 
significant correlation exists between positive COX-2 expression at the time of chest 
wall recurrence and prognosis for post-mastectomy breast cancer patients using tissue 
microarray analysis.   Prognosis was determined by percentage of overall survival, 
distant metastasis-free survival, and local-regional progression-free survival.  
Secondary objectives were to examine the relationship between COX-2 expression 
and time to post-mastectomy chest wall relapse, and ER, PR, and HER-2/neu status at 








PATIENTS and METHODS 
A retrospective review was conducted of 113 patients who were treated with 
radiation therapy for chest wall recurrence at the Yale University Department of 
Therapeutic Radiology between 1979 and 1999.  All patients had an isolated chest 
wall recurrence without evidence of distant metastases at the time of presentation.  
Patients who presented with primarily lymph node metastases, patients with 
simultaneous distant metastases, and patients who received prior radiation therapy 
were excluded from the analysis.   
 Patients underwent surgical excision of the local-regional recurrence when 
feasible, followed by external beam radiation therapy.  Standard radiation treatments 
were given, and patients were treated to a total median dose of 60 Gray (Gy) to the 
chest wall.  Nineteen patients received radiation treatment to the chest wall only, and 
the remaining patients received radiation to the chest wall and regional lymphatics.  
Adjuvant chemotherapy and hormone therapy were administered as deemed necessary 
by physicians.  Forty patients received chemotherapy, and 56 patients received 
hormonal therapy.  The median follow-up after treatment for recurrence was 10.13 
years. 
Patient charts were reviewed for demographics and radiation therapy 
parameters.  Other data including clinical and pathologic staging of initial tumor, 
method of detection, lymph node status, histologic parameters, surgery performed, 
adjuvant treatment for the initial tumor, estrogen receptor status, progesterone receptor 
status, chest wall progression, distant metastases, disease-free survival, and overall 
survival were documented.  All data were entered into a computerized database.  The 
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protocol for chart review and processing of tumor specimens was approved by the 
Yale School of Medicine Human Investigations Committee. 
 Tumor blocks from chest wall recurrence specimens were successfully 
collected from 42 patients, of which 38 were evaluable for tissue microarray analysis.  
The tissue microarray was created by taking core needle sections from existing tumor 
blocks and arranging them into a common paraffin block.   This recipient paraffin 
block was prepared with 2-fold redundancy, which denotes acquiring two samples 
from each of the pre-existing paraffin-embedded tumor specimens.  Two-fold 
redundancy has been shown to correlate well with conventional immunohistochemical 
staining.   One study determined that analysis of two cores was comparable to analysis 
of a whole tissue section in greater than 95% of cases.(39)  It has also been 
demonstrated that many proteins in archival tissue retain their antigenicity for greater 
than 60 years, thus validating the use of these tissues in microarray analysis.   
Cores were initially made in the recipient block to allow placement of tumor 
specimens.  Core depths were made at approximately 2-3 mm while diameters were 
set at 0.6 mm.  “Biopsies” were then taken from the donor block and then placed into 
the cores of the recipient block. These were performed until specimens from all 38 
patients were placed into the recipient paraffin block.  The block was then incubated at 
37 degrees for 10 minutes to allow the cores to adhere to the walls of the holes in the 
array.  The array block was then placed into a microtome for sectioning and cut 5 uM 
thick with a tape-based tissue transfer system (Intrumedics, Hackensack, NJ, U.S.A.)  
After each section was placed on Paraffin Sectioning Aid (PSA-4X) adhesive coated 
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slides, they were radiated with UV light for 20 seconds.  The slide was then placed in 
xylene for 60 seconds and allowed to air dry. 
 Analysis by immunohistochemistry was performed on microarray slides after 
deparaffinization in xylene followed by 100% ethanol.  Samples were then pretreated 
to promote antigen retrieval with the DAKO Target Retrieval Solution (DAKO, 
Carpinteria, CA, U.S.A.)  A 3% hydrogen peroxide solution was then used for 
endogenous peroxidase blocking.  Slides were then incubated with monoclonal 
antibody COX-2 (Cayman Chemical, Ann Arbor, MI, U.S.A.; #160112; dilution 1:50)  
After incubation, the slides were washed in phosphate buffered saline, and a 
biotinylated secondary antibody was applied.  Samples were then applied with DAKO 
streptavidin-horseradish peroxidase using LSAB + Kit.  DAKO DAB (3,3-
diaminobenzidine tetrahydrochloride dehydrate) was then applied as a chromogenic 
substrate.  Tissue microarrays were also stained for HER-2/neu, ER, and PR from a 
previous study that used patients from a similar cohort as this study to create a 
microarray.(40)  
 Analysis of the tissue staining was performed by a single pathologist (V.B.) 
and one of the authors who were both blinded to patient outcome.  Both distribution 
(percentage of tumors stained) and intensity of the cytoplasmic staining were 
documented.  Intensity was recorded on a scale of 0 to 3+ with 3+ having the strongest 
intensity.  The specimens were then given a positive or negative score based on the 
intensity and distribution scores.  Any score with 2 or 3+ with a distribution of >10% 
was considered positive in this study, in accordance with standard clinical practices.(41)  
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These data were added to the computerized database with all clinical and pathologic 
outcomes variables. 
 Chart review for data collection, collection of chest wall recurrence tissue for 
tissue microarray analysis, and reading of slides with pathologist for scoring were 
performed by the student.  Creation of tissue microarray and staining of prepared 
slides by Cox-2 antibody were performed by the tissue microarray lab and 
immunohistochemistry lab respectively at Yale University School of Medicine. 
 The Prodas Data Base System (Conceptual Software, Houston, TX) was used 
to assess patient data and statistics.  The Cox regression model was used to test 
clinical and pathologic factors by both univariate and multivariate analysis.  The life-
table method was used to calculate survival curves and the Mantel-Hanszel chi-square 
test to measure differences in survival curves.  This generation of data was performed 









One hundred thirteen patients presented to the Department of Therapeutic 
Radiology at Yale-New Haven Hospital between January 1979 and December 1999 
for radiation treatment to their chest wall for local-regional recurrence of breast 
cancer.  The mean +/- standard deviation (SD) age at initial diagnosis for these 113 
patients was 52.3 years +/- 13.7 years.   The mean +/- SD age at presentation with a 
first isolated chest wall recurrence was 56.9 years +/- 14.5 years.  The mean time to 
the initial chest wall recurrence was 4.6 years.  The median follow-up after initial 
diagnosis was 13.7 years, and the follow-up after treatment for local-regional 
recurrence was 10.1 years. 
 Of 113 patients, 98 were Caucasian, 10 were African American and 5 were 
from other racial groups.  All patients received simple, modified, or radical 
mastectomy for their initial tumor.  The mean +/- SD size of the tumor at initial 
diagnosis of breast cancer was 3.3 cm +/- 2.1 cm.  The mean number of axillary lymph 
nodes sampled was 14.4 +/- 9.2 lymph nodes, with a mean +/- SD of 3.7 +/- 6.9 
positive lymph nodes.  Half of the patients (n = 57) received adjuvant chemotherapy 
and 33 patients received adjuvant hormone therapy at the time of diagnosis of their 
original breast carcinoma.  The mean +/- SD time between initial diagnosis and chest 
wall recurrence was 4.6 years +/- 4.6 years.  Within 5 years, 66% of patients had 
experienced their recurrence; and, by 10 years, 90% of patients had developed a 
recurrence.  At the time of chest wall relapse, the mean +/- SD size of the recurrence 
tumor was 1.6 cm +/- 1.0 cm (median, 1.5 cm; range, 0.5-5.0 cm; n = 78). Clinical 
outcomes for entire patient population are summarized in Table 1.  Overall survival 
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after original diagnosis was 69% at 5 years and 44% at 10 years.  Overall survival 
after chest wall recurrence was 46% at 5 years and 28% at 10 years.  The distant 
metastasis-free rate for all patients after chest wall recurrence was 49% at 5 years and 
40% at 10 years.  Local progression-free survival after chest wall recurrence was 83% 
at 5 years and 79% at 10 years. 
Table 2 summarizes the demographic, staging, receptor status, and treatment 
parameters at both initial diagnosis and time of chest wall relapse for the cohort of 38 
patients included in the tissue microarray. Mean age at diagnosis was 56.7 years with a 
range from 35-92 years.  Pathologic T status at the time of primary diagnosis was 
found to be predominantly T2 with the second most common status being T3.  Patients 
were also predominantly found to have negative lymph node status at the time of 
original diagnosis (23/38).  There was one patient with unknown lymph node status.  
Estrogen and progesterone receptor status were approximately equally distributed 
among positive, negative, and unknown status.  The majority of patients received 
modified radical mastectomy at the time of primary diagnosis (34/38) as opposed to 
total mastectomy (3/38) or radical mastectomy (1/38).  At the time of chest wall 
relapse, patients predominantly underwent excisional biopsy (33/38).  Most patients 
also did not receive chemotherapy at the time of recurrence (30/38), although most 
received hormone therapy (25/38).  There were no significant differences between this 
selected cohort of 38 patients and the overall group of 113 patients with respect to the 
major clinical characteristics and outcomes.  The 5-year overall survival after primary 
diagnosis of all patients (n=113) was 69% while those in the array (n=38) was 78%.  
The 5-year distant metastases-free survival after primary diagnosis was 69% of all 
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patients compared to 67% of those in the array.  Finally, the 5-year local progression-
free survival after chest wall relapse was 83% for all patients compared to 73% of 
those in the array. 
Cox-2 staining was predominantly cytoplasmic. Using the criteria of 2-3+ 
staining in greater than 10% of cells, 13 of 38 (34%) were considered positive.   The 
majority of patients underwent complete excision of their recurrence tumors (33/38). 
Those who underwent biopsy were in complete remission following external beam 
radiation therapy.   Only 8/38 patients received adjuvant chemotherapy while 25/38 
patients were known to receive hormone therapy at the time of chest wall relapse.  
There were no significant differences in treatment (surgery, chemotherapy or 
hormonal therapy) as a function of COX-2 status (Table 3).  Among patients with 
positive COX-2 status, 12 of 13 (92%) received an excisional biopsy at the time of 
chest wall relapse while among those with negative COX-2 status, 21 of 25 (84%) 
underwent this procedure.  Nine of 13 (69%) of positive COX-2 patients received 
hormone therapy at the time of chest wall relapse while 16 of 22 (73%) of negative 
COX-2 patients received this therapy.  Finally, 3 of 13 (23%) of positive COX-2 
patients received chemotherapy at chest wall relapse while 5 of 25 (20%) of negative 
COX-2 patients underwent this route. 
 Correlation of COX-2 expression with various molecular markers, disease-free 
interval, and chest wall progression is summarized in Table 4.  COX-2 expression was 
found to be positively correlated with HER-2/neu status, early time to chest wall 
recurrence, and chest wall progression.  All were statistically significant. When HER-
2/neu status was analyzed, 9 of 14 patients (64%) with positive HER-2/neu status had 
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positive COX-2 expression.  This compares with only 5 of 14 patients (36%) with 
positive HER-2/neu status who had negative COX-2 expression.  In regards to time to 
chest wall recurrence, patients were divided into two groups of early recurrence and 
late recurrence.  Early recurrence was defined as <24 months.  Seven of 11 patients 
(64%) who tested positive for COX-2 demonstrated early recurrence while only 6 of 
27 patients (22%) who tested positive for COX-2 showed late recurrence.    In chest 
wall progression analysis, 7 of 11 (64%) of patients who tested positive for COX-2 
expression developed another chest wall recurrence after treatment for their original 
chest wall relapse, while 6 of 27 (22%) of positive COX-2 patients did not. 
COX-2 expression was negatively correlated with both ER and PR status, both 
with statistical significance.  When ER status was analyzed, 5 of 23 (22%) of patients 
with positive ER status demonstrated positive COX-2 expression.  This was in 
contrast to 18 of 23 (78%) of patients with positive ER status demonstrating negative 
COX-2 expression.  In regards to PR status, only 2 of 15 (13%) of patients with 
positive PR status demonstrated positive COX-2 expression while 13 of 15 (87%) 
demonstrated negative COX-2 expression. 
  Evaluations of COX-2 expression in relation to outcomes are summarized in 
Table 5.  It is worth noting that the 5-year distant metastases-free rate after primary 
diagnosis for COX-2 negative patients was 79% while the rate for COX-2 positive 
patients was 41% (Figure 1).  This was significant with a p-value of 0.029.  The five 
year local progression-free rate for COX-2 negative patients was 87% while the rate 
for COX-2 positive patients was 38% (Figure 2).  This was highly significant with a p-
value of 0.003.   
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A multivariate model, taking into account all molecular markers (Her-2/neu, 
ER, and PR), as well as time to recurrence was performed on the 38 patients.  COX-2 
overexpression was still found to be a significant predictor of chest wall progression 
(HR = 4.91; CI = 1.09-22.1; P = 0.038).  In the analysis for distant metastases free 
survival, significant predictors were COX-2 expression (HR = 5.25; CI = 1.44-19.2; P 
= 0.01) and positive HER-2/neu status (HR = 0.22; CI = .054-0.92; P = 0.038).  PR 




Despite receiving treatment for local-regional recurrence after mastectomy, 
prognosis is poor for these patients and much research has been directed at 
determining the factors that lead to this poor prognosis.  The location, extent and size 
of recurrence, number of recurrences, number of recurrence nodules, primary lymph 
node status, ER status of primary, ER and PR status of recurrence, and age at time of 
recurrence have all been reported to be indicators of prognosis.(4, 5, 9, 12, 17-19)   A large 
number of studies have reported that the most significant factor for distant metastases 
and survival is the disease-free interval, or interval to recurrence from primary 
diagnosis.  Decreased disease-free interval, or early recurrence has been associated 
with ultimately poor outcome in the majority of these studies.(4, 5, 9, 12, 17-19, 42, 43)  
Despite these clinical and pathological prognostic parameters, there is a need to 
determine molecular markers to more accurately guide clinical management.  
Unfortunately, it has been difficult to accrue an adequate number of patients for large 
prospective randomized studies following women after chest wall recurrence.  As a 
result, Haffty et al conducted a retrospective study in order to explore the prognostic 
significance of estrogen receptor, progesterone receptor, p53, HER-2/neu, and cyclin 
D at chest wall relapse.  Significant factors for distant metastasis after local recurrence 
were time to recurrence and PR status, and for local-regional disease progression was 
HER-2/neu status.(40)  The distant metastasis-free survival rate for patients with 
positive PR status was 84%, compared to 38% in those with negative PR status.  
Patients with positive HER-2/neu status had a local-regional progression-free rate of 
59% while patients with negative HER-2/neu status had a rate of 92%.  Additional 
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biological markers need to be assessed to more clearly define prognosis and assist the 
physician in selecting therapy regimens catered for high-risk patients.  One marker 
that has been the focus of active investigation is COX-2. 
In our study, a uniform cohort of patients who developed chest wall relapse 
and received radiation therapy were selected to assess the prognostic significance of 
COX-2 after relapse.  Although there was no significant difference in overall survival 
between COX-2 positive and negative patients, patient numbers were relatively small 
to detect survival differences.  The resulting analysis demonstrated that patients who 
overexpressed COX-2 had a lower chance of being free of distant metastases and 
higher chance of chest wall progression both on univariate and multivariate analysis.  
Patients with positive COX-2 expression had a 5-year distant metastases-free rate of 
41% while those with negative COX-2 expression had a rate of 79% after primary 
diagnosis.  The results of the 5-year local progression free rate was even more 
significant at 38% with positive COX-2 expression and 87% with negative expression.  
These poor prognostic findings are consistent with a previous study that found the 
distribution and intensity of COX-2 expression from tissue microarray analysis to 
correlate significantly with diminished disease-free survival in breast cancer patients, 
although in this study COX-2 also correlated with decreased overall survival.(44)  
Paraffin-embedded tumor specimens from 23 women with invasive cancer were 
stained for COX-2 expression.  The 5-year overall survival rate was 100% for patients 
with less than 75% of breast cancer cells expressing COX-2 protein compared with 
49% for patients with greater than or equal to 75% expression (p = 0.044).  The study 
also found that younger patients with invasive breast cancer may have a greater 
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percentage of COX-2 expression in their cancers.  A significant association has also 
been found between COX-2 overexpression and distant metastasis in breast cancer.(45)   
In this study, archival specimens of human breast cancer (n = 29) were collected and 
analyzed after staining with COX-2 antibodies.  COX-2 overexpression occurred in 
37.9% of their sample study.  Previous studies have also demonstrated that positive 
COX-2 expression is likely associated with poor outcome due to its correlation with 
poor prognostic factors such as large tumor size, high histological grade, axillary node 
metastases,(20) and lymphovascular invasion.(46) Furthermore in our study, COX-2 
positivity more likely resulted in early local-regional recurrence, or time to recurrence 
in less than 2 years (P = 0.015). This is significant because as stated before, early 
recurrence has been associated with poor prognosis.  COX-2 was also found to be 
negatively correlated with ER (P = 0.045) and PR status (P = 0.028) at recurrence in 
our analysis.  This finding is consistent with two recent studies that also analyzed 
COX-2 expression using tissue microarray analysis in breast cancer.(20, 46)  Because 
positive ER(47) and PR status(48) has been found to be associated with good prognosis, 
this inverse association with these two markers most likely indicates poor prognosis 
for this cohort of patients.  
A marker that occurs in 20-30% of human breast cancers and has been 
correlated with poor prognosis is HER-2/neu.(49-53)  Press et al demonstrated that HER-
2/neu gene amplification in the absence of adjuvant therapy is an independent 
predictor of poor clinical outcome and is a stronger predictor than tumor size.  Patients 
with small tumors who demonstrated HER-2/neu gene amplification were at increased 
risk of recurrence and disease-related death.(51)  Another study by Seshadri et al 
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concluded that HER-2/neu amplification is an independent predictor of shorter 
disease-free survival in both node-negative and node-positive patients.(52)  Our results 
demonstrated that COX-2 expression was positively correlated with HER-2/neu status 
(P = 0.003), thereby indicating poor prognosis.  Other studies have also confirmed a 
positive correlation between these two markers.  Two recent studies showed that 
elevated COX-2 expression was correlated with the presence of HER-2 oncogene 
amplification in human breast cancers.(20, 54) Howe et al demonstrated that treatment 
with celecoxib, a COX-2 inhibitor, significantly reduced the incidence of mammary 
tumors in mice overexpressing wild-type neu protein and caused about a 50% 
reduction in mammary prostaglandin E2 (PGE2) levels.  Because mammary glands 
from these mice models expressed all four PGE2 receptor subtypes, it was suggested 
that signaling through PGE2 receptor subtypes is important for the development of 
mammary tumors.(55)  Benoit et al further showed that COX-2 inhibition reduced 
HER-2/neu proteins levels and acted synergistically with trastuzumab, an anti-HER-2 
monoclonal antibody in breast cancer cell lines.(56)  Concurrent administration of 
COX-2 inhibitors and HER2/neu antibodies for treatment experimental colorectal 
cancer inhibited tumor growth more effectively than when either was administered 
alone.(57)   
More pertinent to our study is the possibility that COX-2 expression may be 
involved with decreased radiosensitivity during treatment of recurrence.  Other studies 
have shown this relationship between COX-2 and radiosensitivity.  In vitro studies 
demonstrated that a selective COX-2 inhibitor, SC-236, in glioma tumor cell culture 
medium enhanced cell killing by ionizing radiation.  When administered in 
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combination with local radiation, SC-236 caused a greater than additive increase in 
tumor growth delay.(58)  Two recent reports concluded that SC-236 markedly increased 
tumor radioresponse in NFSA(59) and FSA sarcoma(60) bearing mice without greatly 
affecting normal tissue radioresponse.  Other studies have shown that prostaglandins 
may serve as radioprotectors.(61)  Although the mechanism is not well understood, it is 
thought that prostaglandins may protect cellular repair mechanisms(62) or inhibit 
radiation-induced apoptosis.  Additional studies should be performed to elucidate the 
association of COX-2 expression and diminished radiosensitivity. 
The methods in our study included use of tissue microarray, which was 
composed of 0.6 mm cores from original tissue specimens.  The validity of using these 
cores to represent larger tissues has been confirmed in a variety of cancers such as 
head and neck, lung, and breast.(39, 63, 64)  An advantage to using this technique was that 
all specimens were processed simultaneously using the same conditions during 
immunohistochemistry, thus resulting in experimental uniformity.  Tissue specimens 
collected at chest wall relapse were relatively homogeneous.  Chest wall specimens 
were only collected from patients who did not present with simultaneous distant 
metastases.  A monoclonal COX-2 antibody was used which may have improved 
specificity for COX-2 compared with a polyclonal antibody.     
There were also some limitations to this study.  Although the method of 
immunohistochemistry is relatively fast and readily available in most pathology 
departments, it is a test subject to interobserver variability.  The reading of stained 
microarray slides is also subjective and may result in variability among pathologists. 
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Other limits of this study included its retrospective design and relatively small sample 
size.  Additional studies need to be carried out to validate these findings. 
Due to the poor prognosis associated with increased COX-2 expression in 
tumors, COX-2 inhibitors as potential therapeutic targets remain an active area of 
research.  Various selective COX-2 inhibitors have been shown to slow tumor growth 
in experimental animals.(65, 66)  Kishi et al reported that SC-236 was found to inhibit 
tumor growth on its own, decrease PGE2 levels in sarcoma FSA tumors, and inhibit 
neoangiogenesis. One study showed that  NS-398, a COX-2 selective inhibitor, 
induced apoptosis in colorectal tumor cells which was independent of COX-2 protein 
expression.(67)  Celecoxib has been shown to decrease tumor size when compared to 
control groups in rat models.(68)  In another study by Masferrer et al, COX-2 was found 
to suppress tumor growth by inhibiting angiogenesis.  COX-2 was detected in the 
angiogenic vasculature in most of human colon, prostate, lung, and breast tumors.  In 
addition, celecoxib dose-dependently inhibited tumor growth and the number and size 
of lung metastases in two animal models of Lewis lung carcinoma and the human 
colon carcinoma HT-29.  It is noteworthy that the expression of COX-2 in these 
models was mainly limited to the angiogenic blood vessels, the preexisting vasculature 
adjacent to the primary tumor, and the blood vessels invading the metastatic lesions, 
and not the cancer cells themselves.  In the same study, celecoxib was also a potent 
inhibitor of angiogenesis in the rat corneal model.   
Numerous mechanisms have been proposed attempting to elucidate the 
correlation between COX-2 expression and tumorigenesis. One theory suggests that 
COX-2 catalyzed products such as prostaglandins may directly break down into a 
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mutagen and form adducts with deoxynucleosides.(69)  Prostaglandins, more 
specifically PGE2, are also known to be potent immunosuppressants.  PGE2 blocks the 
anti-tumor activity of macrophages and natural killer cells,(70, 71)  and inhibits 
production of cytotoxic lymphokines.  These activities may block natural surveillance 
mechanisms to inhibit tumor growth and spread. COX-2 has also been hypothesized to 
induce carcinogenesis through regulation of apoptosis.  Rat intestinal epithelial cells 
transfected with COX-2 showed increased adhesion to extracellular matrix, resistance 
to butyrate-induced apoptosis, and elevated expression of bcl-2, a protein which 
inhibits apoptosis.(72)  COX-2 may also affect tumorigenesis by dysregulating cell 
growth.  It has been proposed that increased duration of G1 phase of the cell cycle 
may cause resistance of cells that permanently express COX-2 to undergo 
programmed death.(73)  It has also been suggested that COX-2 is correlated with 
angiogenesis.  COX-2 showed a significant linear correlation (P = 0.001) with staining 
of CD31, an endothelial cell marker of angiogenesis in breast cancer tissue.(74)  CD31, 
which is also known as platelet-endothelial cell adhesion molecule-1, is thought to 
play a role in various endothelial cell functions including angiogenesis, migration, and 
transmigration of leukocytes across endothelium.  This correlation with angiogenesis 
is significant because some studies have suggested that angiogenesis may be inversely 
associated with survival.(75) 
 In conclusion, our study showed that for patients who develop a local-regional 
recurrence after mastectomy, positive COX-2 expression at the time of recurrence is a 
sign of poor prognosis.  These patients have a lower chance of expressing favorable 
prognostic markers such as ER and PR, and a higher chance of expressing poor 
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prognostic markers such as HER-2/neu.  In addition, they have a greater possibility of 
local progression and distant metastases.  These results may suggest that COX-2 may 
play a role in decreased radiosensitivity at the time of local-regional relapse, and that 
COX-2 inhibition with or without anti-HER2/neu therapy during chest wall radiation 
may improve prognosis.  More specifically, COX-2 inhibitors may provide a relatively 
safe and inexpensive adjuvant to chest wall irradiation.  Prospective randomized trials 
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Outcomes and Survival Data for 113 Patients 
Endpoint Actuarial 
rate at 5 yrs 
+/- SE (%) 
Actuarial rate 
at 10 yrs +/- SE 
(%) 
Overall survival 
after chest wall 
recurrence 
 
46 +/- 4.9 
 
28 +/- 4.8 
Distant metastasis-




49 +/- 5.3 
 
40 +/- 5.9 
Local progression-




83 +/- 3.6 
 
79 +/- 4.1 





































Age at diagnosis (yrs) 38 56.7 35-92 
Follow-up from original 
diagnosis (yrs) 
38 21.1 7-45 
T status at original diagnosis    
   Pathologic T status    
      T1 7   
      T2 17   
      T3 8   
      T4 1   
   Unclear original clinical T  
   status 
5   
Lymph node status at original  
   Dx 
   
   No. with positive lymph  
   nodes 
14   
   No. with negative lymph  
   nodes 
23   
   Unknown 1   
Receptor status at original 
diagnosis 
   
   Estrogen receptor    
      Positive 13   
      Negative 14   
      Unknown 11   
Progesterone receptor    
   Positive 12   
   Negative 12   
   Unknown 14   
Surgery performed    
   Total mastectomy 3   
   Modified radical  
   mastectomy 
34   
   Radical mastectomy 1   
Adjuvant systemic therapy    
   Hormone therapy    
      Given 11   
      None given 27   
   Chemotherapy    
12         Given 
      None given 26   
Surgery at CWR    
 35
     Excisional biopsy 33   
     Incisional biopsy 5   
Chemotherapy at CWR    
     Given 8   
     None given 30   
Hormone therapy at CWR    
     Given 25   
     None given 10   




Correlation of Cox-2 with Clinical Characteristics of 38 Patients 
Characteristic COX-2 Pos COX-2 Neg 
Surgery at CWR   
   Excisional biopsy 12/13 21/25 
   Incisional biopsy 1/13 4/25 
Hormone Therapy at CWR   
   Given 9/13 16/22 
   Not given 4/13 6/22 
Chemotherapy at CWR   
   Given 3/13 5/25 
   Not given 10/13 20/25 



















Correlation of COX-2 with ER, PR, HER-2/neu, Time to CWR, 
 and Chest wall progression 





ER Status    
     Pos 5/23 (22%) 18/23 (78%) 0.045 
     Neg 8/15 (53%) 7/15 (47%)  
PR Status    
     Pos 2/15 (13%) 13/15 (87%) 0.028 
     Neg 11/23 (48%) 12/23 (52%)  
HER-2/neu    
     Pos 9/14 (64%) 5/14 (36%) 0.003 
     Neg 4/24 (17%) 20/24 (83%)  
Time to CW 
Recurrence 
   
     Early (< 2 yrs) 7/11 (64%) 4/11 (36%) 0.015 
     Late ( > 2 yrs) 6/27 (23%) 21/27 (77%)  
CW progression    
     Pos 7/11 (64%) 4/11 (36%) 0.015 
     Neg 6/27 (22%) 21/27 (78%)  
ER = estrogen receptor; PR = progesterone receptor; Pos = positive;  
































Five yr survival after CWR 
(%) 
47 56 .32 
Five yr distant mets-free 
rate after primary dx (%) 
41 79 .029 
Five yr local progression-
free rate after CWR (%) 
38 87 .003 
Pos: positive; Neg: negative; yr: year; dx: diagnosis; CWR: chest 

























Figure 2. Local chest wall progression free rate by COX-2.  
 
 
 
 
 
 
 
 
